Patents Assigned to INSERM (Institut National de la Santé et de la Recherche Médicale)
-
Patent number: 11685792Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.Type: GrantFiled: May 21, 2020Date of Patent: June 27, 2023Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Yves Levy, Jean-Francois Eliaou, Armand Bensussan, Nathalie Bonnefoy-Berard
-
Publication number: 20230192772Abstract: Peptides endowed with an anti-inflammatory, anti-angiogenic and/or antimicrobial activity, a medicament or a pharmaceutical composition including such peptides, and the use thereof in the prevention or treatment of inflammatory diseases, and more particularly inflammatory diseases due to or associated with microbial infections, or in the prevention or treatment of angiogenesis-related diseases.Type: ApplicationFiled: December 22, 2017Publication date: June 22, 2023Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS-SUD 11, UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICOInventors: Claire LACOMBE, Constance AUVYNET, Yvonne ROSENSTEIN, Emmanuelle SACHON
-
Publication number: 20230172919Abstract: An insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment, and in particular for preventing or treating the loss of vision induced by retinal detachment. Also, a composition including the insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment and a device including the composition.Type: ApplicationFiled: March 26, 2021Publication date: June 8, 2023Applicants: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Florian SENNLAUB, Jean-Baptiste CONART, José-Alain SAHEL
-
Patent number: 11654055Abstract: The sensory substitution system includes a portable matrix of exciters that can be worn by a user in such a way that the exciters are placed against the skin of a user, as well as a control circuit for the exciters of the matrix. An asynchronous signal source provides the control circuit with an asynchronous signal representative of visual information organised according to a matrix of pixels. This asynchronous signal includes, for each pixel, successive events associated in an asynchronous manner with the pixel.Type: GrantFiled: December 7, 2017Date of Patent: May 23, 2023Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Guillaume Chenegros, Ryad Benosman, Kevin Arth, Sio-Hoi Ieng
-
Publication number: 20230149405Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.Type: ApplicationFiled: April 7, 2021Publication date: May 18, 2023Applicants: LABORATOIRES C.T.R.S., INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), FONDATION IMAGINE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS-SACLAYInventors: Christine BODEMER, Céline GRECO, Claude BOUCHEIX, Jean-Pascal CONDUZORGUES, Joel SCHLATTER, Salvatore CISTERNINO
-
Publication number: 20230149512Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.Type: ApplicationFiled: January 6, 2023Publication date: May 18, 2023Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITEInventors: David KLATZMANN, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
-
Patent number: 11650214Abstract: The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.Type: GrantFiled: December 9, 2020Date of Patent: May 16, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Côte d'Azur, CHU de NiceInventors: Thierry Passeron, Florence Joly
-
Publication number: 20230142905Abstract: A method for predicting the return to functional autonomy in a subject suffering from an acute event, including the steps of i) determining neopterin level in a biological sample obtained from the subject; ii) comparing the level with its predetermined reference neopterin level and iii) predicting that the subject will have a long time to return to functional autonomy when the level of neopterin is higher than its predetermined reference neopterin level or predicting that the subject will have a short time to return to functional autonomy when the level of neopterin is lower than its predetermined reference neopterin level.Type: ApplicationFiled: April 23, 2021Publication date: May 11, 2023Applicants: SORBONNE UNIVERSITE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Delphine SAUCE, Martin LARSEN, Jacques BODDAERT, Hélène VALLET
-
Publication number: 20230147657Abstract: In the field of immunotherapy, a chimeric antigen receptor (CAR) specific for-human CD45RC. Also, the immune cells expressing this CAR and the use thereof as a medicament. In particular, the use of this CAR for preventing or treating CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, lymphoma or cancer), or graft-versus-host disease (GVHD).Type: ApplicationFiled: March 19, 2021Publication date: May 11, 2023Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), NANTES UNIVERSITEInventors: Carole GUILLONNEAU, Ignacio ANEGON
-
Publication number: 20230140419Abstract: A system for automatic evaluation of cognition and consciousness of a subject, the system including a micro-controller, a digital-to-analog converter and at least one sensory stimulation element, wherein the system is configured to receive as input an information concerning a stimulation paradigm and to generate as output a sensory stimulation according to the stimulation paradigm and transmit at least one synchronization signal determined by the stimulation paradigm to a device for the acquisition of a physiological signal so as to synchronize the system for stimulation with the device for the acquisition of a physiological signal during an acquisition.Type: ApplicationFiled: October 2, 2020Publication date: May 4, 2023Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITEInventors: Federico RAIMONDO, Jacobo SITT, Lionel NACCACHE
-
Patent number: 11629192Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.Type: GrantFiled: September 4, 2018Date of Patent: April 18, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS CITÉ, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE GRENOBLE ALPES, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE DE BOURGOGNEInventors: Zakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric
-
Patent number: 11618884Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT??/? Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.Type: GrantFiled: November 13, 2018Date of Patent: April 4, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventor: Magali Irla
-
Patent number: 11617560Abstract: The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.Type: GrantFiled: September 15, 2017Date of Patent: April 4, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIME INDUSTRIELLES DE LA VILLE DE PARIS, UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉInventors: Zsolt Lenkei, Mathieu Pernot, Mickael Tanter, Thomas Deffieux
-
Patent number: 11613753Abstract: Using chemical proteomics with a potent unique irreversible inhibitor, inventors found that major brain tubulin carboxypeptidase (TCP) is a complex of vasohibin-1 (VASH1) with the Small Vasohibin-Binding Protein (SVBP). VASH1 and its homologue vasohibin-2 (VASH2), when complexed with SVBP, exhibit robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Accordingly inventors are the first to identify the enzymatic activity of vasohibin and vasohibin/SVBP complex. Knock down of vasohibins or SVBP in cultured neurons results in a marked reduction of tyrosinated ?-tubulin levels and onset of severe differentiation defects. Furthermore, knock down of vasohibins disrupts neuronal migration in developing mouse neocortex. These results establish vasohibin/SVBP complexes as TCP enzymes.Type: GrantFiled: October 26, 2018Date of Patent: March 28, 2023Assignees: LES LABORATOIRES SERVIER, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Annie Andrieux, Marie-José Moutin, Christophe Bosc, Chrystelle Aillaud, Leticia Peris, Philippe Delagrange
-
Patent number: 11607419Abstract: The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): —X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma.Type: GrantFiled: June 6, 2018Date of Patent: March 21, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTESInventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnes Quemenier
-
Patent number: 11607443Abstract: Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.Type: GrantFiled: December 22, 2017Date of Patent: March 21, 2023Assignees: UNIVERSITE TOULOUSE III-PAUL SABATIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANçAIS DU SANGInventors: Jean-Philippe Combier, Anne Prel, Frédéric Deschaseaux
-
Patent number: 11602327Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.Type: GrantFiled: August 28, 2017Date of Patent: March 14, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, TOHOKU UNIVERSITYInventors: Cyril Lafon, Jean-Louis Mestas, Maxime Lafond, Shin-Ichiro Umemura
-
Patent number: 11596698Abstract: The present invention concerns synthetic polynucleotides encoding a human fukutin-related protein (FKRP) wherein the synthetic polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon(s). The synthetic polynucleotides are useful, especially for treating a pathology linked to a FKRP deficiency or induced by a defect in ?-dystroglycan (?-DG) glycosylation, such as LGMD2I.Type: GrantFiled: July 6, 2018Date of Patent: March 7, 2023Assignees: GENETHON, UNIVERSITE D'EVRY-VAL-D'ESSONNE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Isabelle Richard, Evelyne Gicquel-Zouida, William Lostal
-
Patent number: 11583596Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.Type: GrantFiled: September 26, 2018Date of Patent: February 21, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNIONInventors: Olivier Meilhac, Emmanuelle Jestin, Florian Guibbal, Sébastien Benard
-
Patent number: 11579147Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.Type: GrantFiled: September 25, 2018Date of Patent: February 14, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard, Centre Leon BernardInventors: Philippe Naquet, Franck Galland, Virginie Millet, Jean-Yves Blay, Caroline Giessner